Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Nanoparticle-based formulation for drug repurposing in cancer treatment
Introduction of nanomedicine Nanomedicine was first entered the preclinical in the mid-1980s, and the first product is PEGylated adenosine deaminase enzyme that was approved by FDA in early 1990 [ ]. Ever since then, scientists hold great passion in this…